HomeTagsInhibrx

Inhibrx

Biotechnology

European Medicines Agency Grants Orphan Drug Designation to INBRX-109

PR Newswire - August 16, 2022

Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the European Commission ("EC"), based on...

Biotechnology

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

PR Newswire - March 4, 2022

Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the U.S. Food and Drug Administration,...